2Lambert L A,Colacchio T A,Barth R J Jr.Interval hepatic resection of colorectal metastases improves patient selection[J].Arch Surg,2000,135(4):473-479
3Lau T N,Lo R H,Tan B S.Colorectal hepatic metastases:Role of radiofrequency ablation[J].Ann Acad Med Singapore,2003,32(2):212-218.
4Livraghi T,Solbiati L,Meloni F,et al.Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection:the "test-of-time approach"[J].Cancer,2003,97(12):3027-3035.
5Sartori S,Nielsen I,Trevisani L,et al.Contrast-enhanced sonography as guidance for transthoracic biopsy of a peripheral lung lesion with large necrotic areas[J].J Ultrasound Med,2004,23(1):133-136.
2de Gramont A,Figer A,Seymour M,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J] .J Clin Oncol,2000,18(16):2938-2947.
3Bortolami M,Venturi C,Giacomelli L, et al. Cytokine, infiltrating macrophage and T cell-mediated response to development of primary and secondary human liver cancer[J].Dig Liver Dis,2002,34(11):794-801.
4Seifert JK, Morris DL. Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer[J].Ann Surg,1998,228(2):201-208.
5Nordenstrom BE. Impact of biologically closed electric circuits(BCEC)on structure and function[J].Integr Physiol Behav Sci, 1992,27(4):285-303.
7Fong Y,Fortner J,Sun RL,et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer:analysis of 1001 consecutive cases[J]. Ann Surg, 1999,230(3):309-318.
8Teh CS,Ooi LL, Hepatic resection for colorectal metastases to the liver. The National Cancer Centre/Singapore General Hospital experience [J]. Ann Acad Med Singapore,2003,32(2): 196-204.
9Schmidt J, Strotzer M,Fraunhofer S,et al. Intraoperative ultrasonography versus helical computed tomography and computed tomography with arterioportograpby in diagnosing colorectal liver metastases:lesion-by-lesion analysis[J].World J Surg,2000,24(1):43-47.
10McGahan JP, Browning PD,Brock JM,et al. Treatment of liver tumors by percutaneous radiofrequency electrocautery[J]. Semin Interv Radiol, 1993,10(2):143-149.
4Parkin D M, Bray F, Ferlay J,et al. Global cancer statistics,2002.[J].CA Cancer J Clin, 2005,55(2):74- 108.
5Kemeny N. Management of liver metastases from colorectal cancer [J]. Oncology, 2006,20(10) 1161-1176.
6Rusthoven K E, Kavanagh B D, Cardenes H, et al. Multi-institutional phase I / II trial of stereotactic body radiation therapy for liver metastases. [J]. J Clin Oneol, 2009,27(10) :1572- 1578.
7Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastaticcolorectalcancer[J]. N EnglJ Mcd, 2004, 351(4): 337-345.
8Lievre A, Bachet J B, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [J]. CancerRes, 2006,66(8): 3992-3995.
9Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies[J].Cancer Res, 2007, 67(6) :2643-2648.
10Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRASmutation detection in metastatic eoloreetal cancer treated by cetuximab plus chemotherapy[J].Br J Cancer, 2007, 96(8)1166-1169.
